The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of observation-Reference-Cited by-同舟云学术

The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of observation

Published:2007 Issue:5 Volume:56 Page:1433-1439
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Wolfe Frederick,Michaud Kaleb

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference15 articles.

1. Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

2. Lymphoma and rheumatoid arthritis--again

3. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

4. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

5. Risk of lymphoma in patients with RA treated with anti-TNF agents

Cited by 296 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies;Dermatology and Therapy;2023-12-03

2. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study;The Lancet Regional Health - Europe;2023-12

3. Epstein–Barr Virus–Associated Lymphomatoid Papules: A Sign of Immunosuppression Resembling Lymphomatoid Papulosis;The American Journal of Dermatopathology;2023-12

4. Systemic Inflammatory Disorders, Immunosuppressive Treatment and Increase Risk of Head and Neck Cancers—A Narrative Review of Potential Physiopathological and Biological Mechanisms;Cells;2023-09-01

5. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook;Expert Review of Clinical Immunology;2023-08-14